Furthermore, Molecular Partners will receive research funding and can earn more than CHF 1 billion if all development and sales milestones are met for all potential products. Related news: ...
The new test is compatible with Roche's cobas 5800, 6800, and 8800 molecular diagnostic analysers ... of SARS-CoV-2 assays on the cobas 6800/8800 systems since the end of the pandemic.
Basel, 22 January 2025 - Roche (SIX: RO, ROG ... with commercialisation under CE mark expected to follow shortly. “Rapid molecular point-of-care testing can revolutionise the clinical management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback